These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23328188)

  • 1. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM; Panjabi S; Buzinec P; Swindle JP
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
    Neutel J; Shojaee A; Maa JF
    Adv Ther; 2012 Jun; 29(6):508-23. PubMed ID: 22773358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O; Andrews LM; Wang L; Xie L
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness analysis of amlodipine/renin-angiotensin system blocker combinations.
    Ram CV; Vasey J; Panjabi S; Qian C; Quah R
    J Clin Hypertens (Greenwich); 2012 Sep; 14(9):601-10. PubMed ID: 22947358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.
    Swindle JP; Buzinec P; Iorga SR; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2011 Sep; 27(9):1719-31. PubMed ID: 21767101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
    Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.
    Tung YC; Lin YS; Wu LS; Chang CJ; Chu PH
    J Clin Hypertens (Greenwich); 2015 Jan; 17(1):51-8. PubMed ID: 25477188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
    Kumagai N; Onishi K; Hoshino K; Nakamori S; Kitai T; Yazu T; Oota M; Ueda Y; Hiraoka N; Okamoto S; Yamada T; Dohi K; Nakamura M; Ito M
    Clin Exp Hypertens; 2013; 35(5):355-60. PubMed ID: 23072348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
    Signorovitch J; Zhang J; Wu EQ; Latremouille-Viau D; Yu AP; Dastani HB; Kahler KH
    Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA; Chapman RH; Benner JS; Tang SS; Solomon HA; Joyce A; Foody JM
    Am J Cardiovasc Drugs; 2010; 10(3):193-202. PubMed ID: 20387911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
    Malesker MA; Hilleman DE
    Manag Care; 2010 Jul; 19(7):36-42. PubMed ID: 20672530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
    Ogihara T; Fujimoto A; Nakao K; Saruta T;
    Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
    Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
    BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.